Botox maker sees another jackpot in Latisse, due this month
(NEWSER) - The company behind Botox sees another hit with the first federally approved drug for growing longer, fuller eyelashes, the New York Times reports. The $120 monthly price tag for Latisse, based on a glaucoma drug, makes some analysts blink, particularly during recession. “If you think about it in terms of luxury, it’s $4 a day,” counters Allergan’s CEO—similar to the daily coffee fix. More»
